Sun Pharmaceutical Industries shareholding pattern

SUNPHARMA

1731.8

0.50 (-0.03%)
Last updated on 24 Feb, 2026 | 15:47 IST
Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Sun Pharmaceutical Industries Shareholding Pattern

  • 2018-19
  • 2019-20
  • 2020-21
  • 2021-22
  • 2022-23
  • 2023-24
  • 2024-25
  • 2025-26
Total Promoters
Segment
Percent

Total Promoters

54.48%

Mutual Fund

12.09%

Insurance

6.57%

Foreign Institutional Investors

16.12%

Domestic Institutional Investors

2.15%

Retail

8.58%

Others

0.01%

Total Promoters
MAR '25
54.48%
JUN '25
54.48%
SEP '25
54.48%
DEC '25
54.48%

Summary

For Year 2025-26, Sun Pharmaceutical Industries reports the following shareholding: Total Promoters at 54.48%, Mutual Fund at 12.09%, Insurance at 6.57%, Foreign Institutional Investors at 16.12%, Domestic Institutional Investors at 2.15%, and Retail at 8.58%. This breakdown provides a quick snapshot of ownership distribution for Sun Pharmaceutical Industries in 2025-26.

Sun Pharmaceutical Industries FAQs

As of 02-2026, the promoter shareholding in Sun Pharmaceutical Industries stands at 54.48% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.

The FII and DII shareholding of Sun Pharmaceutical Industries is 16.12% and 2.15% respectively.

The retail shareholding of the Sun Pharmaceutical Industries is 8.58%.

Changes in shareholding patterns of Sun Pharmaceutical Industries can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.

Shareholding patterns of Sun Pharmaceutical Industries are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.

The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost